Standardisation of Target Volume Delineation for Carotid-sparing Intensity-modulated Radiotherapy in Early Glottis Cancer.
MetadataShow full item record
AIMS: Recently, carotid-sparing intensity-modulated radiotherapy (IMRT) for early laryngeal glottis (T1/T2N0M0) cancer has generated interest in the hope of avoiding long-term carotid toxicity, as well as concerns relating to geographical misses and long-term normal tissue toxicity. The aim of this review was to summarise the current literature on carotid-sparing IMRT for early glottis cancer, with particular focus on definitions of target volumes and the carotid arteries as organs at risk. In addition, we make suggestions for standardisation of these structures, dose constraints and dose reporting. MATERIALS AND METHODS: From 73 references, 16 articles met the criteria for inclusion in this systematic review. These papers described two case reports, 11 planning studies and three prospective studies. RESULTS: There was variation in all target volume definitions with no clear consensus. The greatest variability was in clinical target volume definition. Carotid artery and spinal cord delineation were not always defined and most studies did not use a carotid artery constraint. Of the eight studies that reported carotid artery delineation, no two studies delineated the same length of carotid artery, yet most studies reported mean doses. Most studies used IMRT with three to seven fields. Five studies used arc therapy and two studies used tomotherapy. CONCLUSION: This review highlights a lack of consensus in target volume definitions in carotid-sparing IMRT. Ultimately, long-term prospective data are required to show the benefit of carotid-sparing IMRT. Pooled data will prove useful as most studies will report on small numbers of patients. Therefore, adopting a consensus now on target volume definition, dose constraints and dose reporting will be crucial.
Version of record
Radiotherapy Planning, Computer-Assisted
License start date
Clin Oncol (R Coll Radiol), 2017, 29 (1), pp. 42 - 50
Showing items related by title, author, creator and subject.
LAUNCH OF THE BREAST SCREENING AFTER RADIOTHERAPY DATASET - AN ENGLAND WIDE INITIATIVE TO IMPROVE SCREENING FOR BREAST CANCER IN 9,000 WOMEN AT HIGH RISK FOLLOWING RADIOTHERAPY TO BREAST TISSUE UNDER AGE 36 Radford, J; Howell, S; Vaughan, K; Goode, V; Worthington, D; Yates-Bolton, N; Payne, E; Jenkins, J; Sibbering, M; Swerdlow, A; Cowan, R (2016-10)
Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer. Haviland, JS; Hopwood, P; Mills, J; Sydenham, M; Bliss, JM; Yarnold, JR (2016-06)In radiotherapy trials, normal tissue effects (NTE) are important end points and it is pertinent to ask whether patient-reported outcome measures (PROMs) could replace clinical and/or photographic assessments. Data from ...
Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation. Haviland, JS; Bentzen, SM; Bliss, JM; Yarnold, JR (2016-09-22)Tests of tumour treatment time effect in patients prescribed post-operative radiotherapy for early breast cancer have focussed on time to start of radiotherapy rather than overall treatment time. The START randomised trials ...